{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:56:20Z","timestamp":1788537380037,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.ejca.2010.04.031","type":"journal-article","created":{"date-parts":[[2010,6,9]],"date-time":"2010-06-09T08:51:44Z","timestamp":1276073504000},"page":"2389-2398","source":"Crossref","is-referenced-by-count":32,"title":["Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines"],"prefix":"10.1016","volume":"46","author":[{"given":"C.","family":"Falandry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Freyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejca.2010.04.031_bib1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00043426-199124000-00004","article-title":"Human granulocyte colony-stimulating factor: its basic aspects and clinical applications","volume":"13","author":"Asano","year":"1991","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2010.04.031_bib2","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2010.04.031_bib3","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1517\/14712598.4.12.1897","article-title":"The colony-stimulating factors: use to prevent and treat neutropenia and its complications","volume":"4","author":"Komrokji","year":"2004","journal-title":"Expert Opin Biol Ther"},{"issue":"21","key":"10.1016\/j.ejca.2010.04.031_bib4","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.04.031_bib5","doi-asserted-by":"crossref","unstructured":"Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008;(4):CD003189.","DOI":"10.1002\/14651858.CD003189.pub4"},{"issue":"6","key":"10.1016\/j.ejca.2010.04.031_bib6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7326\/0003-4819-147-6-200709180-00010","article-title":"Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection","volume":"147","author":"Sung","year":"2007","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1016\/j.ejca.2010.04.031_bib7","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2010.04.031_bib8","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2010.04.031_bib9","doi-asserted-by":"crossref","first-page":"i80","DOI":"10.1093\/annonc\/mdi813","article-title":"ESMO recommendations for the application of hematopoietic growth factors","volume":"16","author":"Greil","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.04.031_bib10","doi-asserted-by":"crossref","unstructured":"Greil R, Psenak O. Hematopoietic growth factors: ESMO recommendations for the application. Ann Oncol 2007;18(Suppl 2):ii89\u201391.","DOI":"10.1093\/annonc\/mdm052"},{"key":"10.1016\/j.ejca.2010.04.031_bib11","doi-asserted-by":"crossref","unstructured":"Greil R, Psenak O, Roila F. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol 2008;19(Suppl 2):ii116\u20138.","DOI":"10.1093\/annonc\/mdn107"},{"issue":"6","key":"10.1016\/j.ejca.2010.04.031_bib12","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2010.04.031_bib13","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1200\/JCO.2004.00.7955","article-title":"Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study","volume":"23","author":"Timmer-Bonte","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2010.04.031_bib14","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.2000.18.8.1764","article-title":"Growth factor usage patterns and outcomes in the community setting: collection through a practice-based computerized clinical information system","volume":"18","author":"Swanson","year":"2000","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.ejca.2010.04.031_bib15","doi-asserted-by":"crossref","first-page":"9079","DOI":"10.1200\/JCO.2004.00.1297","article-title":"Insurance status and the use of guideline therapy in the treatment of selected cancers","volume":"23","author":"Harlan","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2010.04.031_bib16","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.1996.14.9.2511","article-title":"Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology","volume":"14","author":"Bennett","year":"1996","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2010.04.031_bib17","first-page":"1043","article-title":"Analysis of hematopoietic growth factor prescriptions in 19 French Cancer Centers","volume":"85","author":"Gautie","year":"1998","journal-title":"Bull Cancer"},{"issue":"24","key":"10.1016\/j.ejca.2010.04.031_bib18","first-page":"1203","article-title":"Prescription d\u2019un facteur de croissance h\u00e9matopo\u00ef\u00e9tique, le l\u00e9nograstime, en pratique courante. R\u00e9sultats et commentaires, \u00e0 partir d\u2019une enqu\u00eate nationale r\u00e9alis\u00e9e d\u2019avril 1995 \u00e0 mars 1996","volume":"27","author":"Maurice-Tison","year":"1998","journal-title":"La Presse M\u00e9dicale"},{"issue":"10","key":"10.1016\/j.ejca.2010.04.031_bib19","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/jnci\/97.10.710","article-title":"NCCN guidelines advocate wider use of colony-stimulating factor","volume":"97","author":"McNeil","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ejca.2010.04.031_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/hep.21517","article-title":"A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C","volume":"45","author":"Thevenot","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejca.2010.04.031_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2010.04.031_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2010.04.031_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy","volume":"99","author":"Hershman","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"25","key":"10.1016\/j.ejca.2010.04.031_bib24","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1200\/JCO.2007.12.0832","article-title":"Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk","volume":"25","author":"Patt","year":"2007","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2010.04.031_bib25","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2010.04.031_bib26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.293.9.1073","article-title":"Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer","volume":"293","author":"Muss","year":"2005","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.ejca.2010.04.031_bib27","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.1998.16.2.716","volume":"16","author":"Fossa","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2010.04.031_bib28","first-page":"305","article-title":"Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?","volume":"7","author":"Masutani","year":"2000","journal-title":"Oncol Rep"},{"issue":"3\u20134","key":"10.1016\/j.ejca.2010.04.031_bib29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/10428199709114168","article-title":"Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin\u2019s lymphoma: factors influencing chemotherapy administration. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"25","author":"Gisselbrecht","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.ejca.2010.04.031_bib30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.1998.16.1.255","article-title":"Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen","volume":"16","author":"Vaughn","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2010.04.031_bib31","first-page":"1045","article-title":"Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?","volume":"6","author":"Masutani","year":"1999","journal-title":"Oncol Rep"},{"issue":"5","key":"10.1016\/j.ejca.2010.04.031_bib32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-9343(02)01036-7","article-title":"Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis","volume":"112","author":"Lyman","year":"2002","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.ejca.2010.04.031_bib33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00000421-200008000-00017","article-title":"Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study","volume":"23","author":"Gatzemeier","year":"2000","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2010.04.031_bib34","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.bjc.6601708","article-title":"Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin\u2019s lymphoma?","volume":"90","author":"Hackshaw","year":"2004","journal-title":"Brit J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2010.04.031_bib35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<719::AID-CNCR13>3.0.CO;2-V","article-title":"A multicenter randomized phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain","volume":"83","author":"Hidalgo","year":"1998","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2010.04.031_bib36","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.1998.16.8.2651","volume":"16","author":"Levine","year":"1998","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.ejca.2010.04.031_bib37","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1200\/JCO.2005.03.099","article-title":"Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide","volume":"23","author":"Papaldo","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2010.04.031_bib38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2010.04.031_bib39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","article-title":"Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy","volume":"29A","author":"Trillet-Lenoir","year":"1993","journal-title":"Eur J Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2010.04.031_bib40","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin\u2019s lymphoma: a nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2010.04.031_bib41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04450.x","article-title":"Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review","volume":"122","author":"Bohlius","year":"2003","journal-title":"Brit J Haematol"},{"issue":"6","key":"10.1016\/j.ejca.2010.04.031_bib42","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/sj.bjc.6602975","article-title":"A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin\u2019s lymphoma","volume":"94","author":"Burton","year":"2006","journal-title":"Brit J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2010.04.031_bib43","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1200\/JCO.1998.16.8.2708","article-title":"Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma","volume":"16","author":"Tjan-Heijnen","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910003722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910003722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T23:16:21Z","timestamp":1559171781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910003722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":43,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0959804910003722"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.04.031","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}